Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Won, Ji-Youn Han, G. Lee, Seog‐Yun Park, K. Lim, K. Yoon, T. Yun, Heung Kim, J. Lee (2011)
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutationsJournal of Clinical Pathology, 64
R. Downey, T. Akhurst, M. Gonen, Bernard Park, V. Rusch (2007)
Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery, 133 6
Sae-Won Han, Tae-You Kim, P. Hwang, Soohyun Jeong, Jeong-Whun Kim, I. Choi, D. Oh, J. Kim, Dong-Wan Kim, D. Chung, S. Im, Y. Kim, J. Lee, D. Heo, Y. Bang, N. Kim (2005)
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
TJ Lynch, DW Bell, R Sordella, S Gurubhagavatula, RA Okimoto, BW Brannigan (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med, 350
Chun-Ta Huang, R. Yen, M. Cheng, Y-C Hsu, Pin-Fei Wei, Yi-Ju Tsai, Meng-Feng Tsai, J. Shih, Chih‐Hsin Yang, Pan‐Chyr Yang (2010)
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinomaMedical Oncology, 27
A. Cho, I. Lim, I. Na, Du Choe, Joon Park, Byung-il Kim, G. Cheon, C. Choi, S. Lim (2011)
Evaluation of Adrenal Masses in Lung Cancer Patients Using F-18 FDG PET/CTNuclear Medicine and Molecular Imaging, 45
C. Glynn, M. Zakowski, M. Ginsberg (2010)
Are There Imaging Characteristics Associated with Epidermal Growth Factor Receptor and KRAS Mutations in Patients with Adenocarcinoma of the Lung with Bronchioloalveolar Features?Journal of Thoracic Oncology, 5
R. Mak, S. Digumarthy, A. Muzikansky, J. Engelman, J. Shepard, N. Choi, L. Sequist (2011)
Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.The oncologist, 16 3
S. Gettinger (2008)
Targeted therapy in advanced non-small-cell lung cancer.Seminars in respiratory and critical care medicine, 29 3
H. Vesselle, R. Schmidt, Jeffrey Pugsley, Melissa Li, S. Kohlmyer, E. Vallières, D. Wood (2000)
Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.Clinical cancer research : an official journal of the American Association for Cancer Research, 6 10
Hai-rim Shin, Y. Ahn, J. Bae, M. Shin, D. Lee, C. Lee, H. Ohrr, D. Ahn, J. Ferlay, D. Parkin, D. Oh, J. Park (2002)
Cancer Incidence in Korea.Cancer research and treatment : official journal of Korean Cancer Association, 34 6
B. Cho, C. Im, M. Park, S. Kim, Joon Chang, Jong Park, H. Choi, Yu Kim, S. Shin, J. Sohn, Hoguen Kim, J. Kim (2007)
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 18
N. Normanno, A. Luca, C. Bianco, L. Strizzi, M. Mancino, M. Maiello, A. Carotenuto, G. Feo, F. Caponigro, D. Salomon (2006)
Epidermal growth factor receptor (EGFR) signaling in cancer.Gene, 366 1
Roseann Mulloy, A. Ferrand, Youngjo Kim, Raffaella Sordella, D. Bell, D. Haber, K. Anderson, J. Settleman (2007)
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.Cancer research, 67 5
A. Gazdar (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 28
C. Lee, K. Kang, Y. Koh, J. Chang, H. Chung, S. Park, K. Yoo, J. Song (2000)
Characteristics of lung cancer in Korea, 1997.Lung cancer, 30 1
F. Detterbeck, D. Boffa, L. Tanoue (2009)
The new lung cancer staging system.Chest, 136 1
H. Greulich, Tzu-Hsiu Chen, W. Feng, P. Jänne, James Alvarez, M. Zappaterra, Sara Bulmer, D. Frank, W. Hahn, W. Sellers, M. Meyerson (2005)
Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR MutantsPLoS Medicine, 2
A. Jemal, R. Tiwari, Taylor Murray, Asma Ghafoor, A. Samuels, Elizabeth Ward, E. Feuer, M. Thun (2004)
Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 54
SC Huang (2000)
Anatomy of SUV. Standardized uptake valueNucl Med Biol, 27
Aizhi Zhu, H. Shim (2011)
Current Molecular Imaging Positron Emitting Radiotracers in OncologyNuclear Medicine and Molecular Imaging, 45
R. Cerfolio, A. Bryant, B. Ohja, A. Bartolucci (2005)
The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.The Journal of thoracic and cardiovascular surgery, 130 1
J. Minna, J. Roth, A. Gazdar (2002)
Focus on lung cancer.Cancer cell, 1 1
D. Jackman, B. Yeap, L. Sequist, N. Lindeman, A. Holmes, V. Joshi, D. Bell, M. Huberman, B. Halmos, M. Rabin, D. Haber, T. Lynch, M. Meyerson, B. Johnson, P. Jänne (2006)
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or ErlotinibClinical Cancer Research, 12
Y. Won, J. Sung, K. Jung, H. Kong, Sohee Park, Hai-rim Shin, E. Park, Y. Ahn, In Hwang, D. Lee, Jin-Su Choi, W. Kim, Tae-Yong Lee, C. Yoo, J. Bae, O. Kim, W. Chung, In-Sik Kong, D. Lee, Jin-Soo Lee (2009)
Nationwide cancer incidence in Korea, 2003-2005.Cancer research and treatment : official journal of Korean Cancer Association, 41 3
W. Pao, V. Miller (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
K. Zasadny, R. Wahl (1993)
Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction.Radiology, 189 3
R. Downey, T. Akhurst, M. Gonen, A. Vincent, M. Bains, S. Larson, V. Rusch (2004)
Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 16
Daniel Jones (2004)
Anticancer drugs: To the rescue?Nature Reviews Drug Discovery, 3
Sung-Cheng Huang (2000)
Anatomy of SUVNuclear Medicine and Biology, 27
K. Carey, A. Garton, M. Romero, Jennifer Kahler, S. Thomson, S. Ross, Frances Park, J. Haley, N. Gibson, M. Sliwkowski (2006)
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.Cancer research, 66 16
I. Na, B. Byun, KyeongMin Kim, G. Cheon, D. Choe, J. Koh, D. Lee, B. Ryoo, H. Baek, Sang-Moo Lim, S. Yang, C. Kim, Jae Lee (2010)
18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.Lung cancer, 67 1
Nucl Med Mol Imaging (2012) 46:169–175 DOI 10.1007/s13139-012-0142-z ORIGINAL ARTICLE Correlation Between F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer Yun-Jung Choi & Byoung Chul Cho & Yong Hyu Jeong & Hyo Jung Seo & Hyun Jeong Kim & Arthur Cho & Jae Hoon Lee & Mijin Yun & Tae Joo Jeon & Jong Doo Lee & Won Jun Kang Received: 22 March 2012 /Revised: 30 April 2012 /Accepted: 2 May 2012 /Published online: 7 June 2012 Korean Society of Nuclear Medicine 2012 Abstract exon 21 mutation or wild type (P00.003 and 0.009, respec- Purpose Mutations in the epidermal growth factor receptor tively). The EGFR mutation showed prolonged overall sur- (EGFR) gene have been identified as potential targets for the vival (OS) compared to wild-type tumors (P00.004). There treatment and prognostic factors for non-small cell lung was no significant difference in survival according to SUV- cancer (NSCLC). We assessed the correlation between fluo- max. Both OS and progression-free survival of patients with a rodeoxyglucose (FDG) uptake and EGFR mutations, as well mutation in exon 19 were significant longer than in patients as their prognostic implications. with wild-type tumors. Methods A total of 163 patients with
Nuclear Medicine and Molecular Imaging – Springer Journals
Published: Jun 7, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.